First-in-human phase I trial to assess the efficacy and safety of a novel Myc inhibitor

(Vall d'Hebron Institute of Oncology) VHIO-born spin-off Peptomyc S.L. initiates the first-in-human Phase I/II clinical trial with its first compound - a disruptive Myc inhibitor, Omomyc (OMO-103).